Long Term Follow-up of International Randomised Phase 3 Study of Rituximab Versus a Watch and Wait Approach for Patients with Asymptomatic, Low Tumour Burden Follicular Lymphoma Shows Rituximab Is Highly Effective at Delaying Time to New Treatment without Detrimental Impact Following Next Line of Therapy

• DOI: 10.1182/blood-2022-156790
• Publication Date: 2022-11-28T20:45:01Z
• Authors: Michael Northend; William Wilson; Laura Clifton-Hadley; Zaynab Rana; Tanya-Louise Martin; Moya Young; Fiona Miall; David Cunningham; Jan Walewski; Burhan Ferhanoglu; Amanda Johnston; John F. Seymour; David C. Linch; Kirit M. Ardeshna
• Keywords: Follicular lymphoma